|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients
|
| Broadcast content: |
|
| ***24 February 2022: We have updated the document 'Antivirals and neutralising
monoclonal antibodies in the treatment of COVID-19 in hospitalised patients CEM_CMO_2022_0005 to correct a link*** |
This
policy has been updated to reflect the withdrawal of the casirivimab and
imdevimab (Ronapreve) neutralising monoclonal antibody (nMAB) combination as a
treatment option for patients hospitalised due to symptoms of COVID-19. This
withdrawal is in the context of the dominance in the UK population of the
Omicron variant of SARS-CoV-2, against which the casirivimab and imdevimab nMAB
combination is ineffective. Patients in
this cohort may instead be considered for entry into the RECOVERY trial,
which is studying sotrovimab versus standard of care. Genotyping of all
inpatients continues to be encouraged for surveillance purposes, but is no
longer needed to confirm eligibility for any of the current COVID treatment
options. The published policy now
focusses solely on patients with hospital onset COVID infection (additional
criteria apply), for whom nirmatrelvir plus ritonavir (Paxlovid) is now available
as a first-line treatment option. The
intravenous antiviral remdesivir (Veklury) and the monoclonal antibody sotrovimab
(Xevudy) remain available as alternative treatment options in this cohort.
|
| Additional information: |
|
This alert does not need to be cascaded to Primary Care.
|